Skip to content
Company Analysis

Zhengye Biotechnology Holding L ZYBT

A comprehensive view of key metrics, scores, and financial health for Zhengye Biotechnology Holding L

Overview of Zhengye Biotechnology Holding Limited

ZYBT NCM
Healthcare Drug Manufacturers - Specialty & Generic Micro Cap
Zhengye Biotechnology Holding Limited (ZYBT), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $0.78, about 941.0% undervalued vs fair value, -83.1% 1Y return, placing in the top 10% of its sector.
$0.78
1.55%
As of March 13, 2026
Previous close • Vol 90d: 83.1%
52-Week Range
Market Cap
$35.54M
Enterprise Value
$103.37M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Zhengye Biotechnology Holding L.

Top Beats

Quick Facts

Website https://www.jlzybio.com
HQ Jilin
Employees 277
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$7
$8
$9
Current: $0.78 +941% vs base

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$186.4M
Gross Profit
$91.3M
R&D Expense
$12.8M
Operating Income (EBIT)
$18.4M
-4.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
222.6%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$16.0M
120.7% of FCF

Where It Leaks

Cash Flow Health significant issues
Overall assessment of cash flow efficiency and conversion quality.
4
Active Leaks
1/4
Improving
2
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Zhengye Biotechnology Holding L's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
62
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
61
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 97% Coverage
Trade-Off Triangle Visualization A ternary plot showing ZYBT's balance between Growth (17.0%), Profitability (46.1%), and Safety (36.9%). Growth 17% Safety 37% Profitability 46%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

25th percentile vs peers
25
Key Signals
Rev Growth YoY 0.0% 34p Revenue CAGR 3Y -10.5% 21p EPS Growth YoY -64.0% 22p EPS CAGR 3Y -33.8% 18p
Strengths
  • Interest Coverage Ratio in top 20% of peers (4.56, 81th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Debt/Fcf Ratio in top 20% of peers (6.51, 84th percentile)
  • Consistently strong margins across 6 metrics
Risks
  • Growth below peer median (percentile: 25)

Profitability

69th percentile vs peers
69
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

55th percentile vs peers
55
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Zhengye Biotechnology Holding L.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$8.12
- - -
+941.0% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info